Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 FCF Yield % is -133.40 as of Sep. 09, 2026. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,002 Drug Manufacturers companies, PRF Technologies ranks worse than 97.6% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
PRF Technologies FCF Yield % Related Terms
PRF Technologies FCF Yield % Historical Data
* Premium members only.
The historical data trend for PRF Technologies's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's FCF Yield % distribution charts can be found below:
* The bar in red indicates where PRF Technologies's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRF Technologies (PRFX) has a FCF Yield % of -133.40 as of Sep. 09, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on PRF Technologies and its competitors. According to the industry distribution chart, PRF Technologies ranks #978 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 97.6%.
Is PRF Technologies' FCF Yield % too high?
PRF Technologies' current FCF Yield % is -133.40. Based on the distribution chart, PRF Technologies ranks #978 out of 1002 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' FCF Yield % compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #978 out of 1002 companies for FCF Yield %. This places PRF Technologies in the lower half of its industry. The industry median FCF Yield % is 0.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.76, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on PRF Technologies and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current FCF Yield % is -133.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current FCF Yield % of -133.40. The current FCF Yield % is -133.40. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For PRF Technologies (PRFX), the current FCF Yield % is -133.40 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
